Pinsent Masons Advises Accord Healthcare in Exclusive Licence Agreement with Myovant Sciences to Commercialise ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe

Under the terms of the agreement, Myovant will receive an upfront payment of US$50 million, and is eligible to receive milestones which could total up to a further US$90.5 million. Myovant will continue to lead the global development of relugolix and provide initial product supply to Accord. Accord will be responsible for certain local clinical development, all commercialization for its territories, and has the option to manufacture relugolix in the future.

The Pinsent Masons transactions team was led by Life Sciences Transactions partner Gina Bicknell, with primary support from solicitor Kiah York and legal director Mario Subramaniam.